You are here: Industry Insights > Abzena

News List

Abzena Receives $10M Investment from Biospring Partners contractpharma
July 29, 2020
New capital will allow Abzena to further accelerate its growth plans. Abzena drove 80% revenue growth and tripled GMP manufacturing capacity in 1H20.
Abzena Completes ADC Tech Transfer contractpharma
July 24, 2019
Successful technical transfer of Synaffix GlycoConnect ADC Technology to enable use in client projects.
Abzena Bolsters Development Timeline Capabilities contractpharma
June 12, 2019
Unveils 14-month cell line to phase 1 GMP service; appoints Shahram Katousian as head of biologics manufacturing.
Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases pharmafocusasia
March 20, 2019
Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases.
Abzena Invests $20M to Expand Integrated Biotherapeutics Offering contractpharma
November 12, 2018
Abzena Invests $20M to Expand Integrated Biotherapeutics Offering
Abzena Selects Sartorius as U.S. Equipment Supplier contractpharma
September 13, 2018
Sartorius Stedim will equip Abzena's CDMO facilities in Bristol, PA and San Diego, CA with end-to-end process solutions
Abzena and OBI Pharma sign licence deal for ThioBridge technology pharmaceutical-technology
July 13, 2017
UK-based life sciences group Abzena has signed a licensing contract and a master service and clinical supply agreement with Taiwan, Chinaese biopharmaceutical company OBI Pharma to enable process development and manufacturing using ThioBridge.

Previous page 1 2 Next page